secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001171843-25-003881
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharmaceuticals 2025 Annual Meeting results: all proposals approved
--------------------------------------------------------------------------

- Elected Class III directors Ian T. Clark (28.9M for, 10.4M withheld) and Peter A. Thompson (38.8M for, 0.4M withheld).
- Ratified PricewaterhouseCoopers as independent auditor for FY2025: 53.1M for, 0.1M against, 0.1M abstain.
- Non-binding advisory vote on named executive officer compensation passed: 37.1M for, 2.1M against, 63.8k abstain.
- 53.4M shares voted of 68.2M outstanding; broker non-votes of 14.1M on director and compensation proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325003881/0001171843-25-003881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325003881/f8k_061325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer